PeptideStack
5.2kquestions
20kanswers
220users

Is survodutide at 20 mg/mL stable enough for three weeks of multi-withdrawal use?

Asked 12 Aug 2025Modified 8 months agoViewed 14k times
20

The case in front of me: survodutide · 20 mg/mL · three weeks.

I want to know whether there is evidence behind this or only repetition.

I have checked the obvious registries and monographs without success.

Can anyone point me at a primary source, or confirm that there is not one?

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
bacteriostatic-water
bacteriostatic-water

Water for injection containing roughly 0.9 per cent benzyl alcohol as a bacteriostatic agent. It suppresses growth in a multiple-withdrawal vial;…

149 questions
shelf-life
shelf-life

How long a preparation remains within specification: labelled expiry for a sealed lyophilised vial, beyond-use dating after reconstitution, and…

327 questions
survodutide
survodutide

A GLP-1 and glucagon receptor dual agonist with a substantial published MASH dataset. Use this tag for its hepatic endpoints, its dose ladder, and…

225 questions
shareeditfollowflag
JE
askedjuan_esquivel14k1612 Aug 2025
6Same situation here, so I will follow this one. – Dr_Ilse_Vandenberg 2 months ago
5Is the material lyophilised or already in solution? Completely different answer. – Dr_Tomas_Kral 20 days ago
add a comment

4 Answers

Accepted answer first, then by votes
82

Accepted answer

three weeks is 21 days and, on a weekly schedule, 3 stopper punctures out of one vial at 20 mg/mL. Set the chemical question aside for a moment, because the puncture count is the one with a convention attached: 21 days is 0.75 times the twenty-eight days conventionally allowed for a preserved multi-dose preparation once it has been entered. Chemically, 20 mg/mL is high enough that adsorption to the glass is a rounding error and low enough that it is not protecting you from anything. What 3 withdrawals do add is 3 opportunities to introduce air, 3 coring events on the same stopper, and a headspace that grows with every draw — none of which show up on a certificate and all of which are avoided by splitting into aliquots at reconstitution.

The relevant point is that a mass shift of plus one dalton is deamidation and plus sixteen is oxidation, so degradation is often visible in a mass spectrum if anyone looks.

Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.

Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.

Metal-catalysed oxidation of methionine is documented across peptide and protein formulations and is why chelators appear in some formulations.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Swirl, never shake. Aggregation is a handling problem more than a time problem.

shareimprove this answerflag
ED
answered · acceptede_dziedzic51k14713 Nov 2025
7Adding a vote because this deserves more of them. – marta_okonkwo 2 months ago
6Two lots stored differently, reassayed at a year — the difference was smaller than I expected. – lane_transit 18 days ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
31

It helps to be literal here: this is answerable from the chemistry rather than from anecdote, which is unusual and welcome.

Adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.

A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.

Deamidation via the succinimide intermediate is well characterised, with sequence-dependent rates highest for asparagine-glycine motifs.

A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.

shareimprove this answerflag
DK
answereddermot_kiely12k1624 Nov 2025
6Aliquoting before the first freeze is the advice I wish I had read two years ago. – ravenna_pace 6 months ago
add a comment
23

Start with the sequence, because which pathways are available depends on which residues are present.

Freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.

Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

Sequence determines which pathways apply, so general statements are general.

Cold, dry, dark, still. Those four words cover most of the mitigation.

shareimprove this answerflag
DC
answeredDr_Idris_Coulibaly33k13722 Oct 2025
18

Put another way, asparagine and glutamine are the deamidation risk, and methionine is the oxidation risk.

Light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.

Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.

Apparent loss in a dilute preparation is usually adsorption rather than degradation and is worth ruling out first.

At dilute concentrations, suspect adsorption before you suspect chemistry.

edited 29 Nov 2025 by marta_okonkwo — tightened the wording; no substantive change

shareimprove this answerflag
MO
answeredmarta_okonkwo190k2582 Nov 2025
5The desiccant point is under-appreciated and costs nothing to act on. – micron22 2 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.